Small Size Gastrointestinal Stromal TumorsNCT07411118
RCT of EFTR Versus STER for GIST Treatment
A study testing Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR and Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR in people with Small Size Gastrointestinal Stromal Tumors and GIST, run by Chinese University of Hong Kong at 4 sites in 4 countries.
Trial summary
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Small Size Gastrointestinal Stromal Tumors, GIST
- What is being tested?
- Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR and Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 136 participants
- Where
- 4 sitesin 4 countries
- Study dates
- 1 Feb 2025to 1 Feb 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Presence of gastric subepithelial tumor on diagnostic upper endoscopy, and
- Diagnostic EUS and CT scan with intravenous contrast suspicious of GIST arising from muscularis propria layer, size with maximum diameter >=1.0cm and <= 3.5cm, and
- Absence of high risk features, including irregular margins, invasion to surrounding organs, lesion hypervascularity, and
- Endoscopic morphology and location deemed feasible with both EFTR and STER by an expert endoscopist, or
- Histological confirmation of GIST through EUS guided fine needle biopsy (Optional, based on recommendation from guidelines)
Who cannot join
- Patients with tumors deemed not suitable for endoscopic resection (Either EFTR or STER), due to unfavourable location, high risk morphology, or any other reasons.
- Patients with multiple tumors.
- Patients unable or unwilling to provide consent.
- Previous esophageal or gastric surgery.
- Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake general anesthesia for the procedure, including ASA grade III or above.
- Pregnant women or those planning pregnancy or breastfeeding women.
- Uncorrectable coagulopathy defined by international normalized ratio (INR) > 1.5 or platelet count < 50000/µl.
- Patients on double anti-platelet agents or anti-coagulation (Warfarin, heparin or other direct oral anticoagulants)
Trial locations and contacts
4 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
4 sites in 4 countries
China1 site, 1 recruiting
- Not yet recruiting
Department of Gastroenterology, Zhongshan Hospital of Fudan University
Shanghai
Hong Kong1 site, 1 recruiting
- Recruiting
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong
Hong Kong
Hon Chi Yip, MBChB, FRCSEd (General), +852 3505 2956, hcyip@surgery.cuhk.edu.hk
India1 site, 1 recruiting
- Not yet recruiting
Asian Institute of Gastroenterology
Hyderabad
Mohan Ramchandani, ramchandanimohan@gmail.com
Japan1 site, 1 recruiting
- Not yet recruiting
Osaka International Cancer Institute
Osaka
Noriya Uedo, uedou-no@mc.pref.osaka.jp
About this study
Official title: Exposed Endoscopic Full Thickness Resection (EFTR) Versus Submucosal Tunnelling Endoscopic Resection (STER) for Small Gastric Gastrointestinal Stromal Tumor (GIST) - an International Double Blinded Randomized Controlled Trial
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified. We aim to compare the outcomes of endoscopic full thickness resection (EFTR) versus submucosal tunnelling endoscopic resection (STER) for clinical small gastric GIST. We hypothesize that EFTR could achieve better complete margin negative resection than STER without increase in adverse event.
This is an international multi-center double blinded randomized controlled trial involving four high volume centers from Hong Kong, mainland China, India and Japan. Adult patients with clinical 1.0-3.Scm gastric GIST undergoing endoscopic resection would be recruited.
Patients would be randomized to undergo EFTR (intervention) or STER (Control) by expert endoscopists under general anaesthesia according to well published methods.
Read the detailed description
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumors in the GI tract, often located in the stomach. Based on the latest World Health Organization (WHO) classification, all GISTs are now considered as malignant tumors. Large size overtly aggressive GISTs are relatively rare, occurring only in up to 8 per million population. However, smaller sizes GIST in the stomach are relatively common, and was found in up to 20% of patients based on autopsy series.
Conventionally, localized GISTs are treated by surgical resection. Several guidelines recommended resection of all histologically confirmed GIST, while some suggested surveillance if the lesion is small <2cm in size. The principle of surgery for GIST is for en-bloc margin negative complete resection, while lymph node dissection is not required. As such, laparoscopic resection of gastric GIST has been advocated when technically feasible, demonstrating short term benefits in recovery than open surgery, with similar oncological outcomes.
With the technological advances of endoscopic surgery including endoscopic submucosal dissection (ESD) for early epithelial cancers and per-oral endoscopic myotomy (POEM), there was a rapid expansion in the indication of endoscopic surgery, in particular resection of subepithelial tumors (SET) in the gastrointestinal tract, in which a significant proportion are GISTs. Systematic review revealed a shorter procedure time and improved short-term recovery by endoscopic resection versus laparoscopic resection, without significant difference in complication and survival. With the favourable outcomes consistently reported in the literature regarding endoscopic resection of upper gastrointestinal GISTs, several endoscopy and oncology society guidelines are now recommending endoscopic resection as an option for smaller size GISTs in institutions with expertise on therapeutic endoscopy.
Submucosal tunneling endoscopic resection (STER) was first reported by Xu, et al in 2012. The concept of the procedure is to create a submucosal tunnel away from the tumor that arose from the musclaris propria layer while protecting the mucosa directly overlying the lesion, so that only mucosal closure of the tunnel entrance would be required after resection. The technique was first used on esophageal SET, where majority of them are benign leiomyoma. STER was then subsequently applied to other upper gastrointestinal tract lesions including the stomach. The merit of the technique mainly lies in the simplicity of closure of the mucosal incision, which only requires simple through-the-scope (TTS) clips. A schematic diagram of the STER procedure is shown in Figure 1.
Development of various techniques that allowed secure endoscopic water-tight closure of full thickness wall defect has led to increasing application of endoscopic full thickness resection (EFTR). As opposed to the STER procedure, the tumor would be directly resected without creation of a submucosal tunnel. This would create a full thickness defect that required complete closure to avoid gastrointestinal leakage and peritonitis. Various methods have been reported for closure, ranging from simple TTS clip closure, over-the-scope clip closure, clip endo-loop purse string technique, re-openable clip over-the-line method (ROLM), endoscopic suturing etc. With appropriate selection of closure method based on the morphology of the defect, secure closure could be achieved with minimal post-procedural morbidity.
American Society of Gastrointestinal Endoscopy (ASGE) has recently published a guideline on endoscopic full thickness resection, where STER procedure would be classified as exposed tunneled type EFTR. The EFTR procedure mentioned in previous paragraph would be classified as exposed non-tunneled type EFTR. Due to the complexity of the nomenclature, EFTR and STER will be used in the subsequent text for easier understanding of the technique described.
Both EFTR and STER has been increasingly utilized in resecting gastric subepithelial tumors including GISTs. In a recent systematic review of 952 gastric EFTR procedures including 523 GISTs, en-bloc margin negative resection was achieved in 99.3%, with surgical conversion rate of 0.09%. Pooled estimate of major adverse event was only 0.29%. On the other hand, systematic review of 2941 STER procedure reported margin negative resection rate of 92.4% with major adverse event of 1.2%. Of note, when only gastric lesion or lesion arising from muscularis propria layer were considered, the margin negative resection rate dropped to 90.6% and 88.3% respectively. While both procedures remained safe and feasible, margin negative resection appeared to be better achieved with EFTR. In the aforementioned studies, recurrence was observed on 0% and 2.3% of patients after EFTR and STER respectively.
The investigators have recently reported a retrospective analysis comparing EFTR and STER for gastric GISTs. In line with the current literature, complete margin negative resection was achieved in a significantly higher proportion with EFTR than STER (100% versus 80%, p=0.029), while no difference was found in the incidence of post-procedural adverse event. It is believed that EFTR is superior to STER in obtaining clear surgical margin, as dissection within the submucosal tunnel is challenging in achieving a wide margin without breaching tumor capsule, especially when tumor size is larger than 2cm. The concern for inadequate defect closure has also recently been overcome by numerous new developments of full thickness closure methods as described above. In the study, local recurrence was observed in 1 patient after STER, while no recurrence was found in the EFTR group. The event rate of recurrence was both low for both STER and EFTR, thus statistically significant difference could not be detected without a huge sample size. Nonetheless, it is however anticipated that with better margin negative resection, EFTR could achieve a lower recurrence rate for malignant GIST than STER, and margin negative complete resection should be a reasonable surrogate outcome for oncological clearance.
To date there has not been any prospective comparative study comparing EFTR and STER for small size gastric GISTs. The investigators have therefore designed the current international prospective randomized controlled trial aiming to demonstrate the superiority of EFTR in achieving better margin negative resection.
- Conditions
- Small Size Gastrointestinal Stromal Tumors, GIST
- Being tested
- Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR, Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
- Keywords
- EFTR, STER, GIST
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTRProcedure or surgery
The procedure would be performed in similar way as reported in the literature. A therapeutic endoscope would be used and the target lesion identified. After submucosal injection of solution around the lesion, mucosal incision would be performed with dedicated dissection knife, followed by submucosal dissection. After adequate submucosal dissection to expose the muscularis propria layer around the tumor, the muscle layer would be dissected to achieve full thickness resection. Care would be taken to avoid breaching of the tumor capsule during the procedure and to aim for en-bloc tumor resection. During the procedure, countertraction technique could be utilized according to the discretion of the endoscopists. Clip or snare related traction methods such as clip-line traction are allowed depending on the endoscopists' preference. In case of development of significant pneumoperitoneum, decompression could be performed by transcutaneous needle.
Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTRProcedure or surgery
As with exposed EFTR, the STER procedure would also be performed in similar way as reported in literature. After identification of the tumor location, a mucosal incision would be made at 3-4cm proximal to it after submucosal injection of saline mixture. Submucosal tunnel would then be created until identification of the tumor within the tunnel. Circumferential dissection would then be performed around the tumor until complete resection is achieved. During the procedure, the dissection plane would aim to avoid breaching tumor capsule in similar manner with EFTR group. The resected specimen would then be retrieved through the tunnel opening. After confirming adequate haemostasis within the submucosal tunnel, the mucosal incision would be closed with TTS clips. In case of failure of STER, cross-over to EFTR would be allowed in order to achieve tumor resection.
| Study group | Role | What they receive |
|---|---|---|
| Endoscopic full thickness resection (EFTR) Group | Experimental | Patients would be randomized to undergo EFTR by expert endoscopists under general anaesthesia according to well published methods. Receives: Procedure: Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR |
| Submucosal Tunneling Endoscopic Resection (STER) Group | Active comparator | Patients would be randomized to undergo STER by expert endoscopists under general anaesthesia according to well published methods. Receives: Procedure: Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete R0 resection
Complete R0 resection, defined as en-bloc complete endoscopic resection with intact tumor capsule and histological negative resection margins.
Measure unit: % of lesions.
Measured: 1 day
Secondary outcomes (8)
Rate of Intra-procedural adverse events
Intra-procedural adverse events (AE), including specific AE such as haemorrhage, tension capnoperitoneum, injury to adjacent peritoneal organs, unintentional mucosal injury / perforation, failed tumor retrieval, and general AE such as cardiovascular, pulmonary or other anaesthetic related events. All adverse events would be documented and graded based on the Common Terminology Criteria for Adverse Event (CTCAE) version 5.0 and ASGE endoscopic adverse event Lexicon.
Measure unit: % of procedure.
Measured: 1 day
Rate of post-procedural adverse events
Post-procedural adverse events within 30 days, including specific AE such as delayed haemorrhage, peritonitis, intra-abdominal abscess / collection, and general AE such as cardiovascular, pulmonary or other anaesthetic related events. All adverse events would be documented and graded based on the Common Terminology Criteria for Adverse Event (CTCAE) version 5.0 and ASGE endoscopic adverse event Lexicon.
Measure unit: % of procedure.
Measured: 30 days
Procedure time
Defined from beginning of mucosal incision until complete closure of the defect (full thickness defect or tunnel opening) after tumor resection.
Measure unit: Minutes.
Measured: 1 day
Crossover rate to EFTR in STER group
Crossover rate to EFTR due to failure in STER group., defined as proportion of STER-assigned cases requiring crossover to EFTR (%).
Measure unit: % of patients.
Measured: 30 days
Conversion rate to major surgery
Rate of conversion to major surgery as salvage for failure or adverse event, defined as proportion of cases requiring conversion to major surgery (%).
Measure unit: % of patients.
Measured: 30 days
Recurrence rate
Recurrence rate on surveillance endoscopy and Computed Tomography. defined as proportion of patients with local or distant tumor recurrence (%).
Measure unit: % of patients.
Measured: 30 days
Patient-reported VAS scores
Patient reported outcomes on post-procedural pain at Day 1, 3, 7, 14 after procedure, using Visual Analogue Scale (VAS) (range: 1-10), where higher score means higher level of pain.
Measure unit: VAS score (0-10)
Measured: Day 1, 3, 7, and 14 after procedure
Endoscopist-rated procedural difficulty
Endoscopist rating of procedural difficulty, according to Likert scale of 1-5, where higher score indicates more perceived difficulty.
Measure unit: Likert score 1-5
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start1 Feb 2025
- Primary completion1 Dec 2032 (estimated)
- Study completion1 Feb 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (23)Papers the sponsor has linked to this study.
- Other trials for Small Size Gastrointestinal Stromal TumorsStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 136 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Collaborators
- Fudan University, Osaka International Cancer Institute, Asian Institute of Gastroenterology, India
- Responsible party
- Principal investigator, Hon Chi Yip, Chinese University of Hong Kong
- Investigators
- Hon Chi Yip, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07411118
- Sponsor's protocol ID
- CRE-2024.509
- Status last verified
- Feb 2026
- First submitted
- 9 Feb 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
PubMed 20189503Chiu PWY, Yip HC, Chan SM, Ng SKK, Teoh AYB, Ng EKW. Endoscopic full-thickness resection (EFTR) compared to submucosal tunnel endoscopic resection (STER) for treatment of gastric gastrointestinal stromal tumors. Endosc Int Open. 2023 Feb 23;11(2):E179-E186. doi: 10.1055/a-1972-3409. eCollection 2023 Feb.
PubMed 36845271Tun KM, Dhindsa BS, Dossaji Z, Deliwala SS, Narra G, Haque L, Lo CH, Dhaliwal A, Chandan S, Ramai D, Singh S, Adler DG. Efficacy and safety of submucosal tunneling endoscopic resection for subepithelial tumors in the upper GI tract: a systematic review and meta-analysis of >2900 patients. IGIE. 2023 Aug 19;2(4):529-537.e2. doi: 10.1016/j.igie.2023.08.005. eCollection 2023 Dec.
PubMed 41646066Granata A, Martino A, Ligresti D, Tuzzolino F, Lombardi G, Traina M. Exposed endoscopic full-thickness resection without laparoscopic assistance for gastric submucosal tumors: A systematic review and pooled analysis. Dig Liver Dis. 2022 Jun;54(6):729-736. doi: 10.1016/j.dld.2021.09.014. Epub 2021 Oct 13.
PubMed 34654680ASGE Technology Committee; Aslanian HR, Sethi A, Bhutani MS, Goodman AJ, Krishnan K, Lichtenstein DR, Melson J, Navaneethan U, Pannala R, Parsi MA, Schulman AR, Sullivan SA, Thosani N, Trikudanathan G, Trindade AJ, Watson RR, Maple JT. ASGE guideline for endoscopic full-thickness resection and submucosal tunnel endoscopic resection. VideoGIE. 2019 Jun 29;4(8):343-350. doi: 10.1016/j.vgie.2019.03.010. eCollection 2019 Aug.
PubMed 31388606Mahmoud T, Wong Kee Song LM, Stavropoulos SN, Alansari TH, Ramberan H, Fukami N, Marya NB, Rau P, Marshall C, Ghandour B, Bejjani M, Khashab MA, Haber GB, Aihara H, Antillon-Galdamez MR, Chandrasekhara V, Abu Dayyeh BK, Storm AC. Initial multicenter experience using a novel endoscopic tack and suture system for challenging GI defect closure and stent fixation (with video). Gastrointest Endosc. 2022 Feb;95(2):373-382. doi: 10.1016/j.gie.2021.10.018. Epub 2021 Oct 22.
PubMed 34695421Tani Y, Uedo N, Nomura T. Reopenable-clip over-the-line method for closure of gastric endoscopic full-thickness resection defect. Dig Endosc. 2023 Jul;35(5):e85-e86. doi: 10.1111/den.14562. Epub 2023 Apr 19. No abstract available.
PubMed 37076983Zhang Y, Wang X, Xiong G, Qian Y, Wang H, Liu L, Miao L, Fan Z. Complete defect closure of gastric submucosal tumors with purse-string sutures. Surg Endosc. 2014 Jun;28(6):1844-51. doi: 10.1007/s00464-013-3404-7. Epub 2014 Jan 18.
PubMed 24442680Guo J, Liu Z, Sun S, Liu X, Wang S, Ge N, Wang G, Qi Y. Endoscopic full-thickness resection with defect closure using an over-the-scope clip for gastric subepithelial tumors originating from the muscularis propria. Surg Endosc. 2015 Nov;29(11):3356-62. doi: 10.1007/s00464-015-4076-2. Epub 2015 Feb 21.
PubMed 25701060Al-Bawardy B, Rajan E, Wong Kee Song LM. Over-the-scope clip-assisted endoscopic full-thickness resection of epithelial and subepithelial GI lesions. Gastrointest Endosc. 2017 May;85(5):1087-1092. doi: 10.1016/j.gie.2016.08.019. Epub 2016 Aug 26.
PubMed 27569858Chiu PWY, Yip HC, Teoh AYB, Wong VWY, Chan SM, Wong SKH, Ng EKW. Per oral endoscopic tumor (POET) resection for treatment of upper gastrointestinal subepithelial tumors. Surg Endosc. 2019 Apr;33(4):1326-1333. doi: 10.1007/s00464-018-06627-4. Epub 2019 Jan 2.
PubMed 30604266Ye LP, Zhang Y, Mao XL, Zhu LH, Zhou X, Chen JY. Submucosal tunneling endoscopic resection for small upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. Surg Endosc. 2014 Feb;28(2):524-30. doi: 10.1007/s00464-013-3197-8. Epub 2013 Sep 7.
PubMed 24013472Chen T, Zhou PH, Chu Y, Zhang YQ, Chen WF, Ji Y, Yao LQ, Xu MD. Long-term Outcomes of Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Submucosal Tumors. Ann Surg. 2017 Feb;265(2):363-369. doi: 10.1097/SLA.0000000000001650.
PubMed 28059965Chen T, Zhang C, Yao LQ, Zhou PH, Zhong YS, Zhang YQ, Chen WF, Li QL, Cai MY, Chu Y, Xu MD. Management of the complications of submucosal tunneling endoscopic resection for upper gastrointestinal submucosal tumors. Endoscopy. 2016 Feb;48(2):149-55. doi: 10.1055/s-0034-1393244. Epub 2015 Oct 30.
PubMed 26517846Xu MD, Cai MY, Zhou PH, Qin XY, Zhong YS, Chen WF, Hu JW, Zhang YQ, Ma LL, Qin WZ, Yao LQ. Submucosal tunneling endoscopic resection: a new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with videos). Gastrointest Endosc. 2012 Jan;75(1):195-9. doi: 10.1016/j.gie.2011.08.018. Epub 2011 Nov 5. No abstract available.
PubMed 22056087
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exposed Endoscopic Full Thickness Resection (EFTR) Versus Submucosal Tunnelling Endoscopic Resection (STER) for Small Gastric Gastrointestinal Stromal Tumor (GIST) - an International Double Blinded Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07411118
- Acronym / sponsor ID
- CRE-2024.509
- Conditions
- Small Size Gastrointestinal Stromal Tumors, GIST
- Keywords
- EFTR, STER, GIST
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 136 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Collaborators
- Fudan University, Osaka International Cancer Institute, Asian Institute of Gastroenterology, India
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 1 Dec 2032 (estimated)
- Study completion
- 1 Feb 2033 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified. We aim to compare the outcomes of endoscopic full thickness resection (EFTR) versus submucosal tunnelling endoscopic resection (STER) for clinical small gastric GIST. We hypothesize that EFTR could achieve better complete margin negative resection than STER without increase in adverse event.
This is an international multi-center double blinded randomized controlled trial involving four high volume centers from Hong Kong, mainland China, India and Japan. Adult patients with clinical 1.0-3.Scm gastric GIST undergoing endoscopic resection would be recruited.
Patients would be randomized to undergo EFTR (intervention) or STER (Control) by expert endoscopists under general anaesthesia according to well published methods.
Detailed description
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumors in the GI tract, often located in the stomach. Based on the latest World Health Organization (WHO) classification, all GISTs are now considered as malignant tumors. Large size overtly aggressive GISTs are relatively rare, occurring only in up to 8 per million population. However, smaller sizes GIST in the stomach are relatively common, and was found in up to 20% of patients based on autopsy series.
Conventionally, localized GISTs are treated by surgical resection. Several guidelines recommended resection of all histologically confirmed GIST, while some suggested surveillance if the lesion is small <2cm in size. The principle of surgery for GIST is for en-bloc margin negative complete resection, while lymph node dissection is not required. As such, laparoscopic resection of gastric GIST has been advocated when technically feasible, demonstrating short term benefits in recovery than open surgery, with similar oncological outcomes.
With the technological advances of endoscopic surgery including endoscopic submucosal dissection (ESD) for early epithelial cancers and per-oral endoscopic myotomy (POEM), there was a rapid expansion in the indication of endoscopic surgery, in particular resection of subepithelial tumors (SET) in the gastrointestinal tract, in which a significant proportion are GISTs. Systematic review revealed a shorter procedure time and improved short-term recovery by endoscopic resection versus laparoscopic resection, without significant difference in complication and survival. With the favourable outcomes consistently reported in the literature regarding endoscopic resection of upper gastrointestinal GISTs, several endoscopy and oncology society guidelines are now recommending endoscopic resection as an option for smaller size GISTs in institutions with expertise on therapeutic endoscopy.
Submucosal tunneling endoscopic resection (STER) was first reported by Xu, et al in 2012. The concept of the procedure is to create a submucosal tunnel away from the tumor that arose from the musclaris propria layer while protecting the mucosa directly overlying the lesion, so that only mucosal closure of the tunnel entrance would be required after resection. The technique was first used on esophageal SET, where majority of them are benign leiomyoma. STER was then subsequently applied to other upper gastrointestinal tract lesions including the stomach. The merit of the technique mainly lies in the simplicity of closure of the mucosal incision, which only requires simple through-the-scope (TTS) clips. A schematic diagram of the STER procedure is shown in Figure 1.
Development of various techniques that allowed secure endoscopic water-tight closure of full thickness wall defect has led to increasing application of endoscopic full thickness resection (EFTR). As opposed to the STER procedure, the tumor would be directly resected without creation of a submucosal tunnel. This would create a full thickness defect that required complete closure to avoid gastrointestinal leakage and peritonitis. Various methods have been reported for closure, ranging from simple TTS clip closure, over-the-scope clip closure, clip endo-loop purse string technique, re-openable clip over-the-line method (ROLM), endoscopic suturing etc. With appropriate selection of closure method based on the morphology of the defect, secure closure could be achieved with minimal post-procedural morbidity.
American Society of Gastrointestinal Endoscopy (ASGE) has recently published a guideline on endoscopic full thickness resection, where STER procedure would be classified as exposed tunneled type EFTR. The EFTR procedure mentioned in previous paragraph would be classified as exposed non-tunneled type EFTR. Due to the complexity of the nomenclature, EFTR and STER will be used in the subsequent text for easier understanding of the technique described.
Both EFTR and STER has been increasingly utilized in resecting gastric subepithelial tumors including GISTs. In a recent systematic review of 952 gastric EFTR procedures including 523 GISTs, en-bloc margin negative resection was achieved in 99.3%, with surgical conversion rate of 0.09%. Pooled estimate of major adverse event was only 0.29%. On the other hand, systematic review of 2941 STER procedure reported margin negative resection rate of 92.4% with major adverse event of 1.2%. Of note, when only gastric lesion or lesion arising from muscularis propria layer were considered, the margin negative resection rate dropped to 90.6% and 88.3% respectively. While both procedures remained safe and feasible, margin negative resection appeared to be better achieved with EFTR. In the aforementioned studies, recurrence was observed on 0% and 2.3% of patients after EFTR and STER respectively.
The investigators have recently reported a retrospective analysis comparing EFTR and STER for gastric GISTs. In line with the current literature, complete margin negative resection was achieved in a significantly higher proportion with EFTR than STER (100% versus 80%, p=0.029), while no difference was found in the incidence of post-procedural adverse event. It is believed that EFTR is superior to STER in obtaining clear surgical margin, as dissection within the submucosal tunnel is challenging in achieving a wide margin without breaching tumor capsule, especially when tumor size is larger than 2cm. The concern for inadequate defect closure has also recently been overcome by numerous new developments of full thickness closure methods as described above. In the study, local recurrence was observed in 1 patient after STER, while no recurrence was found in the EFTR group. The event rate of recurrence was both low for both STER and EFTR, thus statistically significant difference could not be detected without a huge sample size. Nonetheless, it is however anticipated that with better margin negative resection, EFTR could achieve a lower recurrence rate for malignant GIST than STER, and margin negative complete resection should be a reasonable surrogate outcome for oncological clearance.
To date there has not been any prospective comparative study comparing EFTR and STER for small size gastric GISTs. The investigators have therefore designed the current international prospective randomized controlled trial aiming to demonstrate the superiority of EFTR in achieving better margin negative resection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endoscopic full thickness resection (EFTR) Group | Experimental | Procedure: Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTRPatients would be randomized to undergo EFTR by expert endoscopists under general anaesthesia according to well published methods. |
| Submucosal Tunneling Endoscopic Resection (STER) Group | Active comparator | Procedure: Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTRPatients would be randomized to undergo STER by expert endoscopists under general anaesthesia according to well published methods. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Presence of gastric subepithelial tumor on diagnostic upper endoscopy, and
- Diagnostic EUS and CT scan with intravenous contrast suspicious of GIST arising from muscularis propria layer, size with maximum diameter >=1.0cm and <= 3.5cm, and
- Absence of high risk features, including irregular margins, invasion to surrounding organs, lesion hypervascularity, and
- Endoscopic morphology and location deemed feasible with both EFTR and STER by an expert endoscopist, or
- Histological confirmation of GIST through EUS guided fine needle biopsy (Optional, based on recommendation from guidelines)
Key exclusion criteria (8 listed)
- Patients with tumors deemed not suitable for endoscopic resection (Either EFTR or STER), due to unfavourable location, high risk morphology, or any other reasons.
- Patients with multiple tumors.
- Patients unable or unwilling to provide consent.
- Previous esophageal or gastric surgery.
- Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake general anesthesia for the procedure, including ASA grade III or above.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTRThe procedure would be performed in similar way as reported in the literature. A therapeutic endoscope would be used and the target lesion identified. After submucosal injection of solution around the lesion, mucosal incision would be performed with dedicated dissection knife, followed by submucosal dissection. After adequate submucosal dissection to expose the muscularis propria layer around the tumor, the muscle layer would be dissected to achieve full thickness resection. Care would be taken to avoid breaching of the tumor capsule during the procedure and to aim for en-bloc tumor resection. During the procedure, countertraction technique could be utilized according to the discretion of the endoscopists. Clip or snare related traction methods such as clip-line traction are allowed depending on the endoscopists' preference. In case of development of significant pneumoperitoneum, decompression could be performed by transcutaneous needle. | Procedure or surgery | Endoscopic full thickness resection (EFTR) Group |
| Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTRAs with exposed EFTR, the STER procedure would also be performed in similar way as reported in literature. After identification of the tumor location, a mucosal incision would be made at 3-4cm proximal to it after submucosal injection of saline mixture. Submucosal tunnel would then be created until identification of the tumor within the tunnel. Circumferential dissection would then be performed around the tumor until complete resection is achieved. During the procedure, the dissection plane would aim to avoid breaching tumor capsule in similar manner with EFTR group. The resected specimen would then be retrieved through the tunnel opening. After confirming adequate haemostasis within the submucosal tunnel, the mucosal incision would be closed with TTS clips. In case of failure of STER, cross-over to EFTR would be allowed in order to achieve tumor resection. | Procedure or surgery | Submucosal Tunneling Endoscopic Resection (STER) Group |
Primary outcome
Complete R0 resection
Time frame: 1 day
Complete R0 resection, defined as en-bloc complete endoscopic resection with intact tumor capsule and histological negative resection margins. Measure unit: % of lesions.
8 secondary outcomes
Rate of Intra-procedural adverse events
Time frame: 1 day
Rate of post-procedural adverse events
Time frame: 30 days
Procedure time
Time frame: 1 day
Crossover rate to EFTR in STER group
Time frame: 30 days
Conversion rate to major surgery
Time frame: 30 days
Recurrence rate
Time frame: 30 days
Patient-reported VAS scores
Time frame: Day 1, 3, 7, and 14 after procedure
Endoscopist-rated procedural difficulty
Time frame: 1 day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Background: PubMed 20189503Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
- Background: PubMed 36845271Chiu PWY, Yip HC, Chan SM, Ng SKK, Teoh AYB, Ng EKW. Endoscopic full-thickness resection (EFTR) compared to submucosal tunnel endoscopic resection (STER) for treatment of gastric gastrointestinal stromal tumors. Endosc Int Open. 2023 Feb 23;11(2):E179-E186. doi: 10.1055/a-1972-3409. eCollection 2023 Feb.
- Background: PubMed 41646066Tun KM, Dhindsa BS, Dossaji Z, Deliwala SS, Narra G, Haque L, Lo CH, Dhaliwal A, Chandan S, Ramai D, Singh S, Adler DG. Efficacy and safety of submucosal tunneling endoscopic resection for subepithelial tumors in the upper GI tract: a systematic review and meta-analysis of >2900 patients. IGIE. 2023 Aug 19;2(4):529-537.e2. doi: 10.1016/j.igie.2023.08.005. eCollection 2023 Dec.
- Background: PubMed 34654680Granata A, Martino A, Ligresti D, Tuzzolino F, Lombardi G, Traina M. Exposed endoscopic full-thickness resection without laparoscopic assistance for gastric submucosal tumors: A systematic review and pooled analysis. Dig Liver Dis. 2022 Jun;54(6):729-736. doi: 10.1016/j.dld.2021.09.014. Epub 2021 Oct 13.
- Background: PubMed 31388606ASGE Technology Committee; Aslanian HR, Sethi A, Bhutani MS, Goodman AJ, Krishnan K, Lichtenstein DR, Melson J, Navaneethan U, Pannala R, Parsi MA, Schulman AR, Sullivan SA, Thosani N, Trikudanathan G, Trindade AJ, Watson RR, Maple JT. ASGE guideline for endoscopic full-thickness resection and submucosal tunnel endoscopic resection. VideoGIE. 2019 Jun 29;4(8):343-350. doi: 10.1016/j.vgie.2019.03.010. eCollection 2019 Aug.
- Background: PubMed 34695421Mahmoud T, Wong Kee Song LM, Stavropoulos SN, Alansari TH, Ramberan H, Fukami N, Marya NB, Rau P, Marshall C, Ghandour B, Bejjani M, Khashab MA, Haber GB, Aihara H, Antillon-Galdamez MR, Chandrasekhara V, Abu Dayyeh BK, Storm AC. Initial multicenter experience using a novel endoscopic tack and suture system for challenging GI defect closure and stent fixation (with video). Gastrointest Endosc. 2022 Feb;95(2):373-382. doi: 10.1016/j.gie.2021.10.018. Epub 2021 Oct 22.
- Background: PubMed 37076983Tani Y, Uedo N, Nomura T. Reopenable-clip over-the-line method for closure of gastric endoscopic full-thickness resection defect. Dig Endosc. 2023 Jul;35(5):e85-e86. doi: 10.1111/den.14562. Epub 2023 Apr 19. No abstract available.
- Background: PubMed 24442680Zhang Y, Wang X, Xiong G, Qian Y, Wang H, Liu L, Miao L, Fan Z. Complete defect closure of gastric submucosal tumors with purse-string sutures. Surg Endosc. 2014 Jun;28(6):1844-51. doi: 10.1007/s00464-013-3404-7. Epub 2014 Jan 18.
- Background: PubMed 25701060Guo J, Liu Z, Sun S, Liu X, Wang S, Ge N, Wang G, Qi Y. Endoscopic full-thickness resection with defect closure using an over-the-scope clip for gastric subepithelial tumors originating from the muscularis propria. Surg Endosc. 2015 Nov;29(11):3356-62. doi: 10.1007/s00464-015-4076-2. Epub 2015 Feb 21.
- Background: PubMed 27569858Al-Bawardy B, Rajan E, Wong Kee Song LM. Over-the-scope clip-assisted endoscopic full-thickness resection of epithelial and subepithelial GI lesions. Gastrointest Endosc. 2017 May;85(5):1087-1092. doi: 10.1016/j.gie.2016.08.019. Epub 2016 Aug 26.
- Background: PubMed 30604266Chiu PWY, Yip HC, Teoh AYB, Wong VWY, Chan SM, Wong SKH, Ng EKW. Per oral endoscopic tumor (POET) resection for treatment of upper gastrointestinal subepithelial tumors. Surg Endosc. 2019 Apr;33(4):1326-1333. doi: 10.1007/s00464-018-06627-4. Epub 2019 Jan 2.
- Background: PubMed 24013472Ye LP, Zhang Y, Mao XL, Zhu LH, Zhou X, Chen JY. Submucosal tunneling endoscopic resection for small upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. Surg Endosc. 2014 Feb;28(2):524-30. doi: 10.1007/s00464-013-3197-8. Epub 2013 Sep 7.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hon Chi Yip principal investigator
Chinese University of Hong Kong
4 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR and Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR in people with Small Size Gastrointestinal Stromal Tumors and GIST, run by Chinese University of Hong Kong at 4 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in China, Hong Kong, India, Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hon Chi Yip (+852 3505 2956, hcyip@surgery.cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete R0 resection (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07411118, which also lists 23 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.